Early Investigational and Experimental Therapeutics for the Treatment of Hypertriglyceridemia.
J Cardiovasc Dev Dis
MetadataShow full item record
Parthymos, I., Kostapanos, M. S., Liamis, G., & Florentin, M. (2022). Early Investigational and Experimental Therapeutics for the Treatment of Hypertriglyceridemia.. J Cardiovasc Dev Dis, 9 (2) https://doi.org/10.3390/jcdd9020042
Hypertriglyceridemia has been identified as a risk factor for cardiovascular disease and acute pancreatitis. To date, there are only few drug classes targeting triglyceride levels such as fibrates and ω-3 fatty acids. These agents are at times insufficient to address very high triglycerides and the residual cardiovascular risk in patients with mixed dyslipidemia. To address this unmet clinical need, novel triglyceride-lowering agents have been in different phases of early clinical development. In this review, the latest and experimental therapies for the management of hypertriglyceridemia are presented. Specifically, ongoing trials evaluating novel apolipoprotein C-III inhibitors, ω-3 fatty acids, as well as fibroblast growth 21 analogues are discussed.
Triglycerides, Lipoprotein lipase, Apolipoprotein C-iii, Ω-3 Fatty Acids, Volanesorsen, Fibroblast Growth 21 Factor
External DOI: https://doi.org/10.3390/jcdd9020042
This record's URL: https://www.repository.cam.ac.uk/handle/1810/335425
Attribution 4.0 International
Licence URL: https://creativecommons.org/licenses/by/4.0/